These results are consistent with recent studies showing that depletion of LEDGF/p75 sensitizes mixed-lineage leukemic cells to chemoresistance and that individual or combined silencing of LEDGF/p75 and HRP2 reduces the in vivo growth of treatment-resistant glioma [15,62]. This evidence concerns the gene HDGFL2 and central nervous system cancer.